FDA Fast-Tracks Eli Lilly Foundayo Obesity Pill Approval
The FDA fast‑tracked approval of Eli Lilly’s oral obesity pill Foundayo (generic orforglipron), completing review in 50 days under a new expedited program; the GLP‑1 pill mimics natural appetite hormones and produced a mean 11.2% weight loss (~25 lbs) at 36 mg over more than 16 months versus 2.1% for placebo in trial data, though 5–10% of patients discontinued for GI side effects versus nearly 3% on placebo. Foundayo can be taken without fasting or timing restrictions (unlike Novo Nordisk’s oral Wegovy), will be included in a Trump administration deal to lower GLP‑1 prices, and is priced in the U.S. at $149–$349 per month with insured patients potentially paying about $25/month via a Lilly discount card; Eli Lilly shares rose more than 4% after the approval. The decision arrives amid strong demand for GLP‑1s—more than 600,000 prescriptions for oral Wegovy have been written since December and about 1 in 8 Americans report using injectable GLP‑1 drugs.
📌 Key Facts
- The pill is orforglipron (brand name Foundayo), a GLP‑1 oral drug that mimics natural appetite hormones for weight loss.
- The FDA completed its review in 50 days under a new expedited-approval program, effectively fast‑tracking Foundayo's approval.
- In the pivotal trial (reported in NEJM), patients taking 36 mg orforglipron lost a mean 11.2% of body weight (~25 pounds) over more than 16 months versus 2.1% (~<5 pounds) for placebo; 5–10% of orforglipron patients discontinued due to gastrointestinal side effects versus nearly 3% on placebo.
- Foundayo can be taken without fasting or timing restrictions, unlike Novo Nordisk’s oral Wegovy, which must be taken on an empty stomach with a 30‑minute wait before eating or drinking.
- Novo Nordisk’s oral Wegovy has already seen heavy uptake, with more than 600,000 prescriptions written since its December approval, and about 1 in 8 people in the U.S. have used injectable GLP‑1 drugs (KFF survey), underscoring strong demand for GLP‑1 therapies.
- U.S. cash price ranges are reported at $149–$349 per month depending on dose; insured patients may pay as little as $25/month using a Lilly discount card.
- Foundayo will be included in a Trump administration agreement intended to lower prices on GLP‑1 drugs.
- Eli Lilly’s stock rose more than 4% in Wednesday afternoon trading after the Foundayo approval was announced.
📊 Relevant Data
In 2022, the estimated US adult obesity prevalence was 42.5% overall, ranging from 40.1% for non-Hispanic White males to 56.9% for non-Hispanic Black females, with projections to 46.9% by 2035.
US state-level prevalence of adult obesity by race and ethnicity from 1990 to 2022 and forecasted to 2035 — Institute for Health Metrics and Evaluation
Asian adults were 64% less likely, Black adults 49% less likely, and Hispanic adults 30% less likely than White adults to use obesity-management medications, according to a 2024 analysis of over 1 million US adults eligible for such treatments.
Some racial and ethnic groups may face barriers to obtaining obesity-management medications — Medical Xpress
Racial and ethnic disparities in obesity rates are influenced by a combination of biological factors such as genes and body composition, as well as environmental, cultural, and socioeconomic factors.
Social, cultural and ethnic determinants of obesity — ScienceDirect
📰 Source Timeline (2)
Follow how coverage of this story developed over time
- Confirms the generic name orforglipron and reiterates the brand name Foundayo as a GLP‑1 pill mimicking natural appetite hormones.
- Specifies that FDA completed its review in 50 days under a new expedited-approval program aimed at cutting drug approval times.
- Provides concrete U.S. cash pricing ranges: $149–$349 per month depending on dose, with insured patients potentially paying $25/month via a Lilly discount card.
- States that more than 600,000 prescriptions have already been written for Novo Nordisk’s competing oral Wegovy pill since its December approval.
- Details that about 1 in 8 people in the U.S. have used injectable GLP‑1 drugs, citing a KFF survey.
- Clarifies that Foundayo will be included in a Trump administration deal to lower prices on GLP‑1 drugs.
- Reports that Eli Lilly’s stock rose more than 4% in Wednesday afternoon trading after the approval.
- Adds exact trial outcome wording from NEJM: 11.2% mean weight loss (~25 pounds) at 36 mg over more than 16 months vs 2.1% (~<5 pounds) on placebo, and that 5–10% of patients on orforglipron discontinued due to GI side effects vs nearly 3% on placebo.
- Reiterates usage distinction: orforglipron can be taken without fasting or timing restrictions, while the Wegovy pill must be taken on an empty stomach with a 30‑minute wait before eating or drinking.